RVL Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016
Revenue	49.72	17.5	27.76	240.03	263.7	245.75	218.46
Revenue Growth (YoY)	184.10%	-36.96%	-88.43%	-8.98%	7.31%	12.49%	-
Cost of Revenue	9.46	3.62	3.29	111.63	140.08	125.19	125.62
Gross Profit	40.27	13.88	24.47	128.4	123.62	120.56	92.84
Selling, General & Admin	81.98	87.46	72.82	93.03	74.24	56.95	65.96
Research & Development	3.97	6.93	13.39	32.32	43.69	42.69	29.06
Other Operating Expenses	13.31	2.24	28.91	283.75	104.22	72.99	29.87
Operating Expenses	99.26	96.64	115.12	409.1	222.16	172.63	124.89
Operating Income	-58.99	-82.75	-90.65	-280.7	-98.54	-52.07	-32.05
Interest Expense / Income	0.25	4.02	4.1	18.21	20.79	29.05	20.19
Other Expense / Income	-7.53	-22.17	-9.38	-0.88	-0.66	4.52	-0.17
Pretax Income	-51.71	-64.61	-85.37	-298.02	-118.66	-85.64	-52.07
Income Tax	-0.02	0.32	-5.78	-27.12	-8.98	-44.5	-10.25
Net Income	-51.69	-64.92	-79.59	-270.9	-109.68	-41.14	-41.82
Shares Outstanding (Basic)	90	67	61	52	45	43	1
Shares Outstanding (Diluted)	90	67	61	52	45	43	1
Shares Change	33.32%	11.05%	15.82%	15.66%	5.65%	4184.89%	-
EPS (Basic)	-0.58	-0.96	-1.31	-5.17	-2.42	-0.96	-41.81
EPS (Diluted)	-0.58	-0.96	-1.31	-5.17	-2.42	-0.96	-41.81
Free Cash Flow	-37.68	-56.42	14.51	29.55	33.42	50.94	-58.72
Free Cash Flow Per Share	-0.42	-0.84	0.24	0.56	0.74	1.19	-58.71
Gross Margin	80.98%	79.33%	88.14%	53.49%	46.88%	49.06%	42.50%
Operating Margin	-118.64%	-472.85%	-326.53%	-116.94%	-37.37%	-21.19%	-14.67%
Profit Margin	-103.96%	-370.95%	-286.68%	-112.86%	-41.59%	-16.74%	-19.14%
Free Cash Flow Margin	-75.79%	-322.40%	52.25%	12.31%	12.67%	20.73%	-26.88%
EBITDA	-51.08	-52.41	-60.25	-222.8	-16.3	-10.14	-8.29
EBITDA Margin	-102.74%	-299.48%	-217.02%	-92.82%	-6.18%	-4.13%	-3.80%
Depreciation & Amortization	0.38	8.18	21.03	57.02	81.57	46.45	23.59
EBIT	-51.46	-60.59	-81.28	-279.81	-97.87	-56.59	-31.88
EBIT Margin	-103.50%	-346.19%	-292.76%	-116.57%	-37.12%	-23.03%	-14.59%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).